Among Eph receptors, the role of EphA2 in different types of solid tumors, including carcinomas and sarcomas, is well established but it is often controversial, as EphA2 action can be pro- or antitumorigenic depending on ligand availability and/or cell/cancer model context. The gene discussed is EPHA2; the disease is cancer.